Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese ... has just announced FDA approval of a phase 3 trial for eye drops containing tivanisiran, in ...
Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter. Already approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback